- Home
- GLMD vs XXII Comparison
GLMD vs XXII Comparison
Compare GLMD & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLMD | XXII |
|---|---|---|
| Founded | 2000 | 1998 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 3.3M |
| IPO Year | 2013 | 2011 |
Fundamental Metrics
Financial Performance| Metric | GLMD | XXII |
|---|---|---|
| Price | $0.60 | $0.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 80.4K | ★ 1.2M |
| Earning Date | 05-21-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.96 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,832,530.00 |
| Revenue This Year | N/A | $370.28 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.41 | $0.51 |
| 52 Week High | $2.34 | $11.37 |
Technical Indicators
Market Signals| Indicator | GLMD | XXII |
|---|---|---|
| Relative Strength Index (RSI) | 45.01 | 23.26 |
| Support Level | $0.53 | $0.51 |
| Resistance Level | $0.69 | $1.15 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 14.51 | 20.20 |
Price Performance
Historical ComparisonAbout GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.